Patients with DCIS expressing higher levels of activated c-Src had a poorer cumulative 5 year disease-free survival compared to those with low levels (61.7 vs 92%, P=0.011, Figure 2). This evidence concerns the gene SRC and ductal breast carcinoma in situ.